Hemostasis Products Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 1.84 Bn

Forecast Year, 2035

USD 3.11 Bn

CAGR, 2026 - 2035

5.39%

Report Coverage

Global

What is the Hemostasis Products Market Size?

The global hemostasis products market size was estimated at USD 1.84 billion in 2025 and is predicted to increase from USD 1.94 billion in 2026 to approximately USD 3.11 billion by 2035, expanding at a CAGR of 5.39% from 2026 to 2035. Hemostasis products are frequently used during surgical procedures for chronic illnesses such as cancer, heart disease, and liver disease. The need for hemostasis products is predicted to grow as these circumstances become more commonplace worldwide.

Hemostasis Products Market Key Takeaway

• The global hemostasis products market was valued at USD 1.84billion in 2025.
• It is projected to reach USD 3.11billion by 2035.
• The hemostasis products market is expected to grow at a CAGR of 5.39% from 2026 to 2035.
• North America dominated the global market with the largest market share of 32.62% in 2025.
• Europe is expected to grow at a solid CAGR during the forecast period.
• By product, the topical hemostat segment contributed the highest market share of 75% in 2025.
• By application, the surgery segment holds the largest market share of 35.5% in 2025.
• By end use, the hospitals segment captured the biggest market share of 64.53% in 2025.

Market Overview

The hemostasis products market was projected to be worth several billions of dollars, and forecasts for the coming years indicate that it will continue to rise. The market is growing due to factors such as an aging population and an increase in chronic diseases. Products under the category of hemostasis include a broad range of medications and medical equipment intended to stop bleeding. These goods fall under different categories, such as adhesives, sealants , topical hemostats, and hemostatic agents. Every section addresses clinical requirements and uses.

Applications for hemostasis products can be found in many different medical fields, such as trauma care, general surgery, orthopedic surgery, neurosurgery, and cardiovascular surgery. One major factor driving the industry has been innovation in hemostatic technology. The creation of safer and more effective hemostatic products is the result of developments in materials science, biotechnology , and nanotechnology . The hemostasis products market for these items is rising due to the rise in surgical operations, especially in emerging economies.

In the hemostasis products market, regulatory clearances and compliance criteria are important. To guarantee the safety and effectiveness of their products, companies are required to comply with strict regulatory requirements set by organizations like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Notwithstanding the market's potential for expansion, producers face considerable obstacles from issues like competitive pricing pressure, reimbursement concerns, and the possibility of product recalls. On the other hand, unexplored markets, scientific breakthroughs, and the creation of specialized hemostatic treatments present numerous potentials.

How AI is Assisting the Hemostasis Products Industry to Grow?

AI integrates with surgical sealants and hemostatic agents, along with diagnostic analyzers, to improve performance, mainly in complex, minimally invasive, and even robotic surgeries. AI tools in laboratory settings, along with point-of-care settings, facilitate rapid viscoelastic testing, enabling the selection of tailored products, like optimal sealants. The growing volume of robotic and minimally invasive surgeries needs advanced hemostatic sealants that can be applied through small ports, a demand met by AI-guided technology.

Hemostasis Products Market Growth Factors

• The need for hemostasis products is mostly driven by the increase in surgical operations, including orthopedic, general, cardiovascular, and trauma cases. The hemostasis products market is growing since these medications are necessary to reduce bleeding during and after procedures.
• Hemorrhagic illnesses, including thrombocytopenia, von Willebrand disease, and hemophilia, are becoming more commonplace worldwide. The need for hemostasis products to control bleeding episodes and enhance patient outcomes is fueled by this trend.
• Continuous improvements in hemostatic technology have resulted in the creation of novel products that are easier to use, less likely to cause side effects and have better hemostatic efficacy. The hemostasis products market is growing because of the launch of enhanced hemostasis solutions, which fill gaps in therapeutic needs and increase the range of applications.
• Beyond conventional surgical settings, hemostasis products are being employed more and more in a variety of medical specialties. Among other fields, they find use in wound care treatment, obstetrics and gynecology, gastrointestinal, and interventional cardiology. The hemostasis products market is growing because of the hemostasis products' expanding indications.
• The rising cost of healthcare in both wealthy and developing nations encourages the purchase of cutting-edge tools and technologies, such as hemostasis supplies. Furthermore, several nations have advantageous reimbursement policies for hemostasis products, which promote their wider adoption and support market expansion.

Market Scope

Market Dynamic

Driver

Growing awareness and adoption of minimally invasive surgeries

Hemostasis solutions are essential for preventing bleeding during surgery, and their efficacy is especially important for minimally invasive procedures where access and visibility to the operative site are restricted. Faster hemostasis is made possible by these products, enabling surgeons to perform treatments effectively and safely. Moreover, new hemostasis products created especially for minimally invasive operations have been made possible by technological breakthroughs. Hemostatic agents, sealants, and adhesives are among the goods in this category that are specially designed to satisfy the demands of minimally invasive operations. These demands include ease of application, quick commencement of action, and compatibility with laparoscopic and robotic surgical techniques.

Restraint

Limited clinical evidence

For both patients and clinicians, the hemostasis products market can present serious challenges due to the paucity of clinical data. Hemostasis solutions are essential for maintaining patient safety and good results since they are used to manage bleeding disorders and control bleeding during surgical procedures. Clinical evidence is used by healthcare professionals to assess the effectiveness of various hemostasis products. Uncertainty about the best products for particular patient demographics or clinical settings may arise from a lack of evidence. Limited clinical evidence could make it difficult for hemostasis product producers to set their goods apart from rivals. Firm evidence of superiority or distinct advantages could make it difficult for businesses to increase their market share.

Opportunity

Minimally invasive surgical procedures

Due to a number of factors, including an increase in surgical procedures, improvements in hemostatic products, patient and healthcare professional awareness of the advantages of minimally invasive surgeries, and growing preference for these procedures, the hemostasis products market has been growing steadily. Compared to typical open surgeries, minimally invasive surgical methods have smaller incisions, less stress on the surrounding tissues, quicker recovery periods, and fewer problems. Effective hemostasis, the process of halting bleeding, is necessary for these treatments to be successful.

Segment Insights

Product Insights

The topical hemostat segment held the largest share of the hemostasis products market. These products are used to manage wounds or stop bleeding during surgical procedures. They function by either providing a physical barrier to stop bleeding or by encouraging clotting. Pork or cow gelatin has been refined to create these sponges. They take in blood and act as a matrix for the aggregation of platelets and the development of clots. These goods are made from collagen from cattle or horses. They function by encouraging platelet aggregation and starting the clotting cascade. Human or animal fibrinogen and thrombin are used to make these. Together, they create a fibrin clot where the bleeding is occurring.

The hemostasis products market is driven by a number of factors, including the rise in chronic illness prevalence, the number of surgical procedures, and improvements in hemostatic technologies. The development of innovative hemostatic agents and the rising demand for minimally invasive procedures are also anticipated to contribute to the market's growth.

Hemostasis Products Market Revenue, By Product 2022-2024 (USD Billion)

Application Insights

The surgery segment held the largest share of the hemostasis products market. These are materials that are used to stop more bleeding and encourage clotting in areas that are bleeding. Topical hemostatic agents like thrombin, collagen-based hemostats, gelatin sponges, and oxidized regenerated cellulose (ORC) products are a few examples of them. To stop fluid or air leaks, sealants are used to close and seal wounds or incisions. They are particularly helpful in operations involving delicate tissues or organs when suturing would not be sufficient. They can be synthetic or biological in nature. Fibrinogen and thrombin are sometimes added to sealants to replicate the last phases of the body's clotting cascade. These drugs are frequently utilized during surgeries when more conventional hemostasis techniques are either not possible or not sufficient.

Staples and sutures are necessary instruments for attaining hemostasis by sealing wounds or incisions, even though they are not hemostatic agents in and of themselves. However, new developments in hemostasis products have made absorbable sutures covered with hemostatic agents much more effective at stopping bleeding. Hemostasis during surgery can also be achieved through the use of surgical instruments that coagulate blood vessels and tissues using electrocautery, ultrasonic energy, or other sources of energy. These tools aid in successfully blocking blood vessels to stop bleeding. In order to achieve hemostasis, these mechanical devices are employed to obstruct blood arteries or other structures. They are frequently utilized in both open and minimally invasive operations and come in a variety of forms, such as absorbable ligatures and metallic clips.

Hemostasis Products Market Revenue, By Application2022-2024 (USD Billion)

End Use Insights

The hospitals segment held the largest share in the hemostasis products market. Because so many surgeries are conducted on their grounds, hospitals are the biggest users of hemostasis supplies. Hemostatic drugs may be needed for a variety of treatments, from simple surgeries to intricate interventions, in order to properly control bleeding. Hospital departments include general surgery, orthopedics, neurosurgery, cardiovascular surgery, obstetrics and gynecology, and trauma care units use hemostasis products. Depending on their particular requirements, each of these professions can need a different kind of hemostatic substance. Severe bleeding and traumatic injury situations are common in hospitals, especially those with emergency rooms. Quick hemostasis is essential in these emergency situations to preserve life.

Hospitals frequently favor advanced hemostasis products, such as hemostatic agents containing recombinant factors or advanced biomaterials, since they provide faster and more effective hemostasis. These goods contribute to shorter recovery periods, less blood loss, and better patient outcomes. In the healthcare industry, big hospitals and hospital networks have a lot of purchasing power. They drive competition among suppliers by negotiating contracts with hemostasis product manufacturers to secure attractive prices and terms. Hospitals follow the rules and regulations that control the use of medical equipment and supplies, including hemostasis products. Adherence to regulations guarantees both patient safety and high-quality healthcare.

Hemostasis Products Market Revenue, By End Use 2022-2024 (USD Billion)

Regional Insights

What is the U.S. Hemostasis Products Market Size?

The U.S. hemostasis products market size was valued at USD 558.40 million in 2025 and is projected to reach USD 960.07 million by 2035, registering a CAGR of 5.57% from 2026 to 2035.

North America held the largest share of the hemostasis products market and is expected to maintain this position throughout the forecast period. Hemostasis product sales worldwide are dominated by North America, specifically by the United States and Canada. The frequency of bleeding diseases, the rise in surgical operations, improvements in hemostasis technology, and the aging population all have an impact on the market growth. These developments include the introduction of hemostatic devices, adhesives and sealants , and hemostatic chemicals, which aid in attaining quick hemostasis and lower the possibility of surgical problems. Government organizations like Health Canada in Canada and the Food and Drug Administration (FDA) in the United States strictly oversee the market. Obtaining regulatory permits and adhering to standards are essential for businesses functioning in this industry.

Europe holds a notable share of the global hemostasis products market. Within the larger medical device market in Europe, the hemostasis products market represents a sizeable portion. Hemostasis products are used to treat bleeding disorders like hemophilia, control bleeding during surgical procedures, and treat trauma cases. In a variety of medical settings, such as clinics, ambulatory surgical centers, and hospitals, these products are essential. Chronic conditions, including liver illness, cancer, and cardiovascular disease, can cause bleeding issues. Hemostasis products are in greater demand as these diseases become more common in Europe, and they are used to control bleeding episodes brought on by these illnesses.

Hemostasis Products in Surgical Applications in the Asia Pacific

Asia Pacific shows a significant growth during the forecast period. A massive increase in cardiovascular, orthopedic, and general surgeries demands efficient, quick-acting hemostatic agents to decrease operative time and blood loss. The rising prevalence of chronic diseases among older adults leads to higher surgical needs, thus demanding advanced tissue sealing solutions.

Hemostasis Products in Dental Applications in Latin America

Latin America shows a notable growth during the forecast period. It is driven by rising surgical volumes, a rapidly aging population, and an increasing shift toward complex oral procedures like dental implants. These products are essential for controlling post-extraction bleeding, minimizing infection risks, and improving the success rate of restorative dentistry by ensuring a dry, clean field.

Next-Generation Hemostasis Products Market in MEA

MEA shows a rapid growth during the forecast period. A significant rate of road accidents along with trauma cases in the MEA region necessitates quick-acting, thus effective hemostatic agents in emergency care settings. Rising healthcare investments, mainly in advanced infrastructure, along with the establishment of corporate hospitals in countries such as Saudi Arabia and the UAE, are driving the acceptance of premium hemostatic solutions.

Hemostasis Products Market Companies

• Dexur Inc.: Dexur Inc. offers data analytics, market intelligence, along with sales-targeting tools programmed for life sciences, medical device, and healthcare firms operating within the hemostasis products market.
• Pfizer Inc.: Pfizer Inc. provides a portfolio aimed at surgical hemostatic agents, advanced sealants, and innovative therapies for bleeding disorders. Their products span from conventional topical agents to next-generation biologics for hemophilia.
• Tricol Biomedical: Tricol Biomedical provides advanced chitosan-based hemostatic products programmed for rapid bleeding control. Their products cater to military, emergency responders, and surgical settings, offering immediate, antibacterial, and adhesive wound sealing.
• Medtronic Plc.: Medtronic Plc provides a diverse portfolio of hemostasis products, aimed on advanced surgical energy devices, hemostatic patches, and endoscopic solutions programmed to stop bleeding quickly during surgery, trauma, and gastrointestinal procedures. Their offerings generally focus on topical, advanced, and energetic methods of achieving coagulation, rather than infusible factors.

Other Major Key Players

• Terumo Corporation
• Baxter International, Inc.
• Sysmex Asia Pacific Pte. Ltd.
• Abbott Healthcare Private Limited
• CSL Behring LLC
• Grifols
• S.A.

Segment Covered in the Report

By Product

• Topical Hemostasis
• Infusible Hemostasis
• Advanced Hemostasis

By Application

• Surgery
• Trauma
• Hemophilia
• Myocardial Infarction
• Others

By End-use

• Hospitals
• Ambulatory Surgical Center

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa